{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:52:21Z","timestamp":1774288341023,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-022-02979-5","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T16:04:58Z","timestamp":1668873898000},"page":"731-738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7635-863X","authenticated-orcid":false,"given":"Xiao-xue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-bin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tie-hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-yang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"issue":"4","key":"2979_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jamcollsurg.2013.05.021","volume":"217","author":"RM Dodson","year":"2013","unstructured":"Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013;217(4):736-750.e4.","journal-title":"J Am Coll Surg"},{"issue":"4","key":"2979_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.semradonc.2018.06.010","volume":"28","author":"EC Lo","year":"2018","unstructured":"Lo EC, Rucker A, Federle MP. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma: imaging for diagnosis, tumor response to treatment and liver response to radiation. Semin Radiat Oncol. 2018;28(4):267\u201376.","journal-title":"Semin Radiat Oncol"},{"issue":"18","key":"2979_CR3","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","volume":"341","author":"PC De Groen","year":"1999","unstructured":"De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341(18):1368\u201378.","journal-title":"N Engl J Med"},{"issue":"4","key":"2979_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrgastro.2011.20","volume":"8","author":"T Patel","year":"2011","unstructured":"Patel T. Cholangiocarcinoma\u2013controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189\u2013200.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"2979_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.21037\/cco.2018.07.03","volume":"7","author":"AJ Lee","year":"2018","unstructured":"Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC\/UICC 8th edition updates. Chin Clin Oncol. 2018;7(5):52.","journal-title":"Chin Clin Oncol"},{"issue":"2","key":"2979_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4254\/wjh.v2.i2.58","volume":"2","author":"Z Morise","year":"2010","unstructured":"Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, et al. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2010;2(2):58\u201364.","journal-title":"World J Hepatol"},{"issue":"5","key":"2979_CR7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","volume":"44","author":"C Mosconi","year":"2021","unstructured":"Mosconi C, Solaini L, Vara G, Brandi N, Cappelli A, Modestino F, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-a systemic review and meta-analysis. Cardiovasc Intervent Radiol. 2021;44(5):728\u201338.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2979_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/1471-2407-10-492","volume":"10","author":"YX Chen","year":"2010","unstructured":"Chen YX, Zeng ZC, Tang ZY, Fan J, Zhou J, Jiang W, et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer. 2010;10:492.","journal-title":"BMC Cancer"},{"issue":"1","key":"2979_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/02656736.2020.1763484","volume":"37","author":"G Brandi","year":"2020","unstructured":"Brandi G, Rizzo A, Dall\u2019Olio FG, Felicani C, Ercolani G, Cescon M, et al. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. Int J Hyperthermia. 2020;37(1):479\u201385.","journal-title":"Int J Hyperthermia"},{"issue":"4","key":"2979_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1634\/theoncologist.2007-0252","volume":"13","author":"AF Hezel","year":"2008","unstructured":"Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist. 2008;13(4):415\u201323.","journal-title":"Oncologist"},{"issue":"55","key":"2979_CR11","doi-asserted-by":"publisher","first-page":"93541","DOI":"10.18632\/oncotarget.19972","volume":"8","author":"ZT Shen","year":"2017","unstructured":"Shen ZT, Zhou H, Li AM, Li B, Shen JS, Zhu XX. Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma. Oncotarget. 2017;8(55):93541\u201350.","journal-title":"Oncotarget"},{"issue":"1","key":"2979_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396.","journal-title":"Ann Surg"},{"issue":"6","key":"2979_CR13","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.surg.2012.12.005","volume":"153","author":"O Hyder","year":"2013","unstructured":"Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013;153(6):811\u20138.","journal-title":"Surgery"},{"issue":"8","key":"2979_CR14","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1007\/s00261-021-03107-7","volume":"46","author":"KL Shampain","year":"2021","unstructured":"Shampain KL, Hackett CE, Towfighi S, Aslam A, Masch WR, Harris AC, et al. SBRT for HCC: overview of technique and treatment response assessment. Abdom Radiol (NY). 2021;46(8):3615\u201324.","journal-title":"Abdom Radiol (NY)"},{"issue":"2","key":"2979_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.radonc.2015.04.006","volume":"115","author":"A Huertas","year":"2015","unstructured":"Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Crois\u00e9-Laurent V, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol. 2015;115(2):211\u20136.","journal-title":"Radiother Oncol"},{"issue":"3","key":"2979_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jso.21609","volume":"102","author":"KE Rusthoven","year":"2010","unstructured":"Rusthoven KE, Hasselle MD. SBRT for unresectable HCC: a familiar tune? J Surg Oncol. 2010;102(3):207\u20138.","journal-title":"J Surg Oncol"},{"issue":"7","key":"2979_CR17","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cncr.23787","volume":"113","author":"JH Kim","year":"2008","unstructured":"Kim JH, Yoon HK, Sung KB, Ko GY, Gwon DI, Shin JH, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer. 2008;113(7):1614\u201322.","journal-title":"Cancer"},{"issue":"5","key":"2979_CR18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jvir.2012.01.081","volume":"23","author":"Y Fu","year":"2012","unstructured":"Fu Y, Yang W, Wu W, Yan K, Xing BC, Chen MH. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2012;23(5):642\u20139.","journal-title":"J Vasc Interv Radiol"},{"key":"2979_CR19","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.2147\/CMAR.S172940","volume":"10","author":"X Zheng","year":"2018","unstructured":"Zheng X, Chen B, Wu JX, Jia AY, Rong WQ, Wang LM, et al. Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels. Cancer Manag Res. 2018;10:3973\u201381.","journal-title":"Cancer Manag Res"},{"issue":"1076","key":"2979_CR20","doi-asserted-by":"publisher","first-page":"20170061","DOI":"10.1259\/bjr.20170061","volume":"90","author":"P Sahai","year":"2017","unstructured":"Sahai P, Kumar S. External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence. Br J Radiol. 2017;90(1076):20170061.","journal-title":"Br J Radiol"},{"issue":"4","key":"2979_CR21","first-page":"664","volume":"45","author":"K Sugiyama","year":"2018","unstructured":"Sugiyama K, Kamiyama T, Ohmura T, Nagatsu A, Shimada S, Einama T, et al. A case of locally advanced intrahepatic cholangiocarcinoma successfully treated by conversion surgery after hepatic arterial infusion chemotherapy and radiation therapy. Gan To Kagaku Ryoho. 2018;45(4):664\u20136.","journal-title":"Gan To Kagaku Ryoho"},{"key":"2979_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ctro.2019.07.007","volume":"19","author":"NT Sebastian","year":"2019","unstructured":"Sebastian NT, Tan Y, Miller ED, Williams TM, Alexandra Diaz D. Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma. Clin Transl Radiat Oncol. 2019;19:66\u201371.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2979_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1748-717X-7-67","volume":"7","author":"BM Barney","year":"2012","unstructured":"Barney BM, Olivier KR, Miller RC, Haddock MG. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol. 2012;7:67.","journal-title":"Radiat Oncol"},{"issue":"14","key":"2979_CR24","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"12","key":"2979_CR25","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30(12):1950\u20138.","journal-title":"Ann Oncol"},{"issue":"4","key":"2979_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"EASL-EORTC Clinical Practice Guidelines","year":"2012","unstructured":"EASL-EORTC Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908\u201343.","journal-title":"J Hepatol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02979-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-02979-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02979-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T19:34:00Z","timestamp":1677008040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-02979-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["2979"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-02979-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtaned from the patient included in the case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}